Targeted Deletion of Peroxiredoxin 1 Enhances Anti-Tumor Immunity in Colorectal Cancer by Reprogramming the Immunosuppressive Tumor-Associated Macrophages

Abstract

Peroxiredoxin 1 (PRDX1) overexpression in colorectal cancer (CRC) correlates with poor prognosis and reduced T-cell infiltration. However, the mechanism underlying PRDX1-mediated immune suppression remains elusive. In this study, we found that knockout of PRDX1 robustly suppressed AOM/DSS-induced colonic adenocarcinoma compared with wild-type C57BL/6J mice, accompanied by highly infiltrated CD4⁺/CD8⁺ T cells and reduced CD163⁺ tumor-associated macrophages (TAMs). Furthermore, PRDX1 knockdown in CRC cells inhibited M2 macrophage polarization by impairing hypoxia-inducible factor 1α (HIF-1α)/GLUT-1-mediated glycolysis and lactate secretion. Mechanistically, PRDX1 binds to Cullin-2 as a molecular chaperone, thereby suppressing ubiquitination and degradation of HIF-1α. The PRDX1^Cys83Ser mutant abolished the ability to bind to Cullin-2, suggesting that Cys83 is an active site of PRDX1 in regulating HIF-1α/GLUT-1-mediated glycolysis. Importantly, PRDX1 deletion in macrophages reversed the immunosuppressive phenotype and reciprocally enhanced the phagocytosis, inhibited CRC cell growth and migration. Cytokine assay demonstrated that PRDX1 deficiency increased IL-1β and TNF-α secretion by activating the JAK/STAT1/NF-κB pathway, promoting M1 macrophage polarization. Notably, PRDX1 knockout macrophages inhibited syngeneic tumor growth and enhanced sensitivity to anti-PD-1 therapy in vivo. In conclusion, targeted deletion of PRDX1 enhances anti-tumor immunity in CRC by reprogramming the immunosuppressive TAMs, revealing a novel role of PRDX1 as a potential drug target during anti-tumor immunotherapy.

Keywords

colorectal cancer / immune suppression / macrophage polarization / PRDX1

References

[1] K. X. Lin, A. C. Istl, D. Quan, et al., “PD-1 and PD-L1 Inhibitors in Cold Colorectal Cancer: Challenges and Strategies,” Cancer Immunology, Immunotherapy 72, no. 12 (2023): 3875–3893.

[2] D. T. Le, J. N. Uram, H. Wang, et al., “PD-1 Blockade in Tumors With Mismatch-Repair Deficiency,” New England Journal of Medicine 372, no. 26 (2015): 2509–2520.

[3] M. Yue, S. Hu, H. Sun, et al., “Extracellular Vesicles Remodel Tumor Environment for Cancer Immunotherapy,” Molecular Cancer 22, no. 1 (2023): 203.

[4] H. Tang, Y. Liang, R. A. Anders, et al., “PD-L1 on Host Cells Is Essential for PD-L1 Blockade-Mediated Tumor Regression,” Journal of Clinical Investigation 128, no. 2 (2018): 580–588.

[5] E. Peranzoni, J. Lemoine, L. Vimeux, et al., “Macrophages Impede CD8 T Cells From Reaching Tumor Cells and Limit the Efficacy of Anti-PD-1 Treatment,” PNAS 115, no. 17 (2018): E4041–E4050.

[6] Y. Shu and P. Cheng, “Targeting Tumor-Associated Macrophages for Cancer Immunotherapy,” Biochimica et Biophysica Acta (BBA) – Reviews on Cancer 1874, no. 2 (2020): 188434.

[7] L. Liu, G. Chen, S. Gong, et al., “Targeting Tumor-Associated Macrophage: An Adjuvant Strategy for Lung Cancer Therapy,” Frontiers in Immunology 14 (2023): 1274547.

[8] M. J. Iqbal, A. Kabeer, Z. Abbas, et al., “Interplay of Oxidative Stress, Cellular Communication and Signaling Pathways in Cancer,” Cell Communication and Signaling 22, no. 1 (2024): 7.

[9] R. Shah, B. Ibis, M. Kashyap, and V. A. Boussiotis, “The Role of ROS in Tumor Infiltrating Immune Cells and Cancer Immunotherapy,” Metabolism 151 (2023): 155747.

[10] X. Guan, Y. Ruan, X. Che, and W. Feng, “Dual Role of PRDX1 in Redox-Regulation and Tumorigenesis: Past and Future,” Free Radical Biology and Medicine 210 (2024): 120–129.

[11] Y. W. X. Song, Y. Sun, N. Yu, et al., “PRDX1 Inhibits Ferroptosis by Binding to Cullin-3 as a Molecular Chaperone in Colorectal Cancer,” International Journal of Biological Sciences 20, no. 13 (2024): 5070–5086.

[12] M. Certo, C. H. Tsai, V. Pucino, et al., “Lactate Modulation of Immune Responses in Inflammatory Versus Tumour Microenvironments,” Nature Reviews Immunology 21, no. 3 (2021): 151–161.

[13] Z. H. Wang, W. B. Peng, P. Zhang, et al., “Lactate in the Tumour Microenvironment: From Immune Modulation to Therapy,” Electronic Biomedicine 73 (2021): 103627.

[14] K. Zhao, X. Wang, D. Zhao, et al., “lncRNA HITT Inhibits Lactate Production by Repressing PKM2 Oligomerization to Reduce Tumor Growth and Macrophage Polarization,” Research 2022 (2022): 9854904.

[15] F. Uhlitz, P. Bischoff, S. Peidli, et al., “Mitogen-Activated Protein Kinase Activity Drives Cell Trajectories in Colorectal Cancer,” EMBO Molecular Medicine 13, no. 10 (2021): e14123.

[16] J. Li, C. Wu, H. Hu, et al., “Remodeling of the Immune and Stromal Cell Compartment by PD-1 Blockade in Mismatch Repair-Deficient Colorectal Cancer,” Cancer Cell 41, no. 6 (2023): 1152–1169.e1157.

[17] D. Anantha Rajah, H. S. Tan, and R. Farghadani, “Aptamers as Immune Checkpoint Inhibitors in Cancer Immunotherapy: Targeting CTLA-4/B7 and PD-1/PD-L1 Pathways,” International Immunopharmacology 164 (2025): 115339.

[18] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580.

[19] X. Mu, W. Shi, Y. Xu, et al., “Tumor-Derived Lactate Induces M2 Macrophage Polarization via the Activation of the ERK/STAT3 Signaling Pathway in Breast Cancer,” Cell Cycle 17, no. 4 (2018): 428–438.

[20] O. R. Colegio, N. Q. Chu, A. L. Szabo, et al., “Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid,” Nature 513, no. 7519 (2014): 559–563.

[21] X. Jin, Y. Kuang, L. Li, et al., “A Positive Feedback Circuit Comprising p21 and HIF-1alpha Aggravates Hypoxia-Induced Radioresistance of Glioblastoma by Promoting Glut1/LDHA-Mediated Glycolysis,” Faseb Journal 36, no. 3 (2022): e22229.

[22] X. Liu, G. Zurlo, and Q. Zhang, “The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer,” Advances in Experimental Medicine and Biology 1217 (2020): 173–186.

[23] S. J. Jeong, S. Kim, J. G. Park, et al., “Prdx1 (Peroxiredoxin 1) Deficiency Reduces Cholesterol Efflux via Impaired Macrophage Lipophagic Flux,” Autophagy 14, no. 1 (2018): 120–133.

[24] Y. S. Weng, H. Y. Tseng, Y. A. Chen, et al., “MCT-1/miR-34a/IL-6/IL-6R Signaling Axis Promotes EMT Progression, Cancer Stemness and M2 Macrophage Polarization in Triple-Negative Breast Cancer,” Molecular Cancer 18, no. 1 (2019): 42.

[25] A. Shapouri-Moghaddam, S. Mohammadian, H. Vazini, et al., “Macrophage Plasticity, Polarization, and Function in Health and Disease,” Journal of Cellular Physiology 233, no. 9 (2018): 6425–6440.

[26] Y. Wang, A. Barrett, and Q. Hu, “Targeting Macrophages for Tumor Therapy,” Aaps Journal 25, no. 5 (2023): 80.

[27] S. U. Khan, M. U. Khan, M. Azhar Ud Din, et al., “Reprogramming Tumor-Associated Macrophages as a Unique Approach to Target Tumor Immunotherapy,” Frontiers in Immunology 14 (2023): 1166487.

[28] H. Xu, H. Zhao, C. Ding, et al., “Celastrol Suppresses Colorectal Cancer via Covalent Targeting Peroxiredoxin 1,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 51.

[29] K. Tilekar, N. Upadhyay, C. V. Iancu, et al., “Power of Two: Combination of Therapeutic Approaches Involving Glucose Transporter (GLUT) Inhibitors to Combat Cancer,” Biochimica et Biophysica Acta (BBA) – Reviews on Cancer 1874, no. 2 (2020): 188457.

[30] Y. Cheng, G. Chen, L. Hong, et al., “How Does Hypoxia Inducible Factor-1alpha Participate in Enhancing the Glycolysis Activity in Cervical Cancer?,” Annals of Diagnostic Pathology 17, no. 3 (2013): 305–311.

[31] D. Liakopoulos, T. Busgen, A. Brychzy, et al., “Conjugation of the Ubiquitin-Like Protein NEDD8 to Cullin-2 Is Linked to von Hippel-Lindau Tumor Suppressor Function,” PNAS 96, no. 10 (1999): 5510–5515.

[32] P. H. Maxwell, M. S. Wiesener, G. W. Chang, et al., “The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis,” Nature 399, no. 6733 (1999): 271–275.

[33] C. Fan, S. Yuan, Y. Zhang, et al., “Peroxiredoxin-1 as a Molecular Chaperone That Regulates Glutathione S-Transferase P1 Activity and Drives Mutidrug Resistance in Ovarian Cancer Cells,” Biochemistry and Biophysics Reports 37 (2024): 101639.

[34] C. Ding, X. Fan, and G. Wu, “Peroxiredoxin 1 – An Antioxidant Enzyme in Cancer,” Journal of Cellular and Molecular Medicine 21, no. 1 (2017): 193–202.

[35] W. Lee, K. S. Choi, J. Riddell, et al., “Human Peroxiredoxin 1 and 2 Are Not Duplicate Proteins: The Unique Presence of CYS83 in Prx1 Underscores the Structural and Functional Differences Between Prx1 and Prx2,” Journal of Biological Chemistry 282, no. 30 (2007): 22011–22022.

[36] H. H. Jang, L. KO, Y. H. Chi, et al., “Two Enzymes in One; Two Yeast Peroxiredoxins Display Oxidative Stress-Dependent Switching From a Peroxidase to a Molecular Chaperone Function,” Cell 117, no. 5 (2004): 625–635.

[37] X. Chen, J. Tang, W. Shuai, et al., “Macrophage Polarization and Its Role in the Pathogenesis of Acute Lung Injury/Acute Respiratory Distress Syndrome,” Inflammation Research 69, no. 9 (2020): 883–895.

[38] Y. Zhang, X. Zhang, Y. Meng, et al., “The Role of Glycolysis and Lactate in the Induction of Tumor-Associated Macrophages Immunosuppressive Phenotype,” International Immunopharmacology 110 (2022): 108994.

[39] H. C. Zhou, Y. Xin-Yan, W. W. Yu, et al., “Lactic Acid in Macrophage Polarization: The Significant Role in Inflammation and Cancer,” International Reviews of Immunology 41, no. 1 (2022): 4–18.

[40] W. Zhong, Y. Lu, X. Han, et al., “Upregulation of Exosome Secretion From Tumor-Associated Macrophages Plays a Key Role in the Suppression of Anti-Tumor Immunity,” Cell Reports 42, no. 10 (2023): 113224.

[41] M. Ohkura, S. Fuchimoto, and K. Orita, “Antitumor Effect of Recombinant Human Interleukin-1 Beta Alone and in Combination With Natural human Tumor Necrosis Factor-alpha,” Japanese Journal of Cancer Research 81, no. 10 (1990): 1026–1031.

[42] D. Yang, L. Yang, J. Cai, et al., “Phosphoinositide 3-kinase/Akt and Its Related Signaling Pathways in the Regulation of Tumor-Associated Macrophages Polarization,” Molecular and Cellular Biochemistry 477, no. 10 (2022): 2469–2480.

[43] T. Tian, X. Xie, W. Yi, et al., “FBXO38 Mediates FGL1 Ubiquitination and Degradation to Enhance Cancer Immunity and Suppress Inflammation,” Cell Reports 42, no. 11 (2023): 113362.

[44] D. E. Johnson, R. A. O'Keefe, and J. R. Grandis, “Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer,” Nature Reviews Clinical Oncology 15, no. 4 (2018): 234–248.

[45] A. Assouvie, L. P. Daley-Bauer, and G. Rousselet, “Growing Murine Bone Marrow-Derived Macrophages,” Methods in Molecular Biology 1784 (2018): 29–33.

[46] M. Si, Y. Song, X. Wang, et al., “CXCL12/CXCR7/beta-arrestin1 Biased Signal Promotes Epithelial-to-Mesenchymal Transition of Colorectal Cancer by Repressing miRNAs Through YAP1 Nuclear Translocation,” Cell & Bioscience 12, no. 1 (2022): 171.

[47] D. Wang, X. Wang, Y. Song, et al., “Exosomal miR-146a-5p and miR-155-5p Promote CXCL12/CXCR7-induced Metastasis of Colorectal Cancer by Crosstalk With Cancer-Associated Fibroblasts,” Cell Death & Disease 13, no. 4 (2022): 380.

[48] D. Wang, X. Wang, M. Si, et al., “Exosome-Encapsulated miRNAs Contribute to CXCL12/CXCR4-Induced Liver Metastasis of Colorectal Cancer by Enhancing M2 Polarization of Macrophages,” Cancer Letters 474 (2020): 36–52.

[49] B. Weigmann, I. Tubbe, D. Seidel, et al., “Isolation and Subsequent Analysis of Murine Lamina Propria Mononuclear Cells From Colonic Tissue,” Nature Protocols 2, no. 10 (2007): 2307–2311.

[50] X. Yu, D. Wang, X. Wang, et al., “CXCL12/CXCR4 promotes Inflammation-Driven Colorectal Cancer Progression Through Activation of RhoA Signaling by Sponging miR-133a-3p,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 32.

[51] R. Satija, J. A. Farrell, D. Gennert, et al., “Spatial Reconstruction of Single-Cell Gene Expression Data,” Nature Biotechnology 33, no. 5 (2015): 495–502.

[52] I. Korsunsky, N. Millard, J. Fan, et al., “Fast, Sensitive and Accurate Integration of Single-Cell Data With Harmony,” Nature Methods 16, no. 12 (2019): 1289–1296.

[53] E. Becht, L. McInnes, J. Healy, et al., “Dimensionality Reduction for Visualizing Single-Cell Data Using UMAP,” Nature Biotechnology 37 (2019): 38–44.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.